ஜொன்னா ஸ்ப்பேர்த்துச் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஜொன்னா ஸ்ப்பேர்த்துச். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஜொன்னா ஸ்ப்பேர்த்துச் Today - Breaking & Trending Today

Mavacamten Is Effective in Treating Obstructive Hypertrophic Cardiomyopathy

ACC late-breaking phase 3 data from EXPLORER-HCM trial on first-in-class cardiac myosin inhibitor ....

Carey Kimmelstiel , Jay Edelberg , Johna Spertus , University Of Missouri , Cardiomyopathy Development At Bristol Myers Squibb , Saint Luke Mid America Heart Institute , American College Of Cardiology , Bristol Myers Squibb , American College , Saint Luke , Mid America Heart Institute , Lauer Missouri Endowed Chair , Myers Squibb , Heart Failure , Cardiomyopathy Development , Bristol Myers , Hypertrophic Cardiomyopathy , Cardiac Myosin , Septal Ablation , Treat Hypertrophic Cardiomyopathy , ஜொன்னா ஸ்ப்பேர்த்துச் , பல்கலைக்கழகம் ஆஃப் மிச Ou ரி , துறவி லூக் நடுவில் அமெரிக்கா இதயம் நிறுவனம் , அமெரிக்கன் கல்லூரி ஆஃப் இருதயவியல் , பிரிஸ்டல் மைஸ் ஸ்க்விப்ப் , அமெரிக்கன் கல்லூரி ,

Bristol Myers Squibb Presents Late-Breaking Phase 3 Data Demonstrating Health Status Benefits of Mavacamten in Patients with Obstructive Hypertrophic Cardiomyopathy at American College of Cardiologys 70th Annual Scientific Session

Posted on
1113
Bristol Myers Squibb (NYSE: BMY) today announced a new analysis of data from the Phase 3 EXPLORER-HCM study evaluating mavacamten, an investigational, first-in-class cardiac myosin inhibitor, in patients with obstructive hypertrophic cardiomyopathy (oHCM), which was presented at the American College of Cardiology’s 70
th Annual Scientific Session (ACC.21), with simultaneous publication in
The Lancet. At 30 weeks, the change in Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ OSS) was greater in mavacamten patients than placebo, with similar benefits across all KCCQ subscales. Moreover, a greater proportion of mavacamten patients achieved a very large, clinically meaningful improvement (≥20 points) in the KCCQ OSS, compared to placebo, 36% [33/92] vs. 15% [13/88]. A change of at least 5 points is required to be considered clinically significant. These results were p ....

Johna Spertus , Bristol Myers Squibb , Susan Francis , American College Of Cardiology , Clinical Researchi Session , Exchange Commission , University Of Missouri , American College , Annual Scientific Session , Featured Clinical Researchi Session , Hot Topics Channel , Clinical Director , Outcomes Research , Saint Luke , Mid America Heart Institute , Lauer Missouri Endowed Chair , Hypertrophic Cardiomyopathy , Myers Squibb , Private Securities Litigation Reform Act , Annual Report , Quarterly Reports , Current Reports , ஜொன்னா ஸ்ப்பேர்த்துச் , பிரிஸ்டல் மைஸ் ஸ்க்விப்ப் , சூசன் பிரான்சிஸ் , அமெரிக்கன் கல்லூரி ஆஃப் இருதயவியல் ,

EXPLORER-HCM Analysis Find Mavacamten Improves Health Status in Symptomatic Obstructive HCM

EXPLORER-HCM Analysis Find Mavacamten Improves Health Status in Symptomatic Obstructive HCM
acc.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from acc.org Daily Mail and Mail on Sunday newspapers.

Johna Spertus , Kansas City Cardiomyopathy Questionnaire , Clinical Topics , Heart Failure , Acute Heart , ஜொன்னா ஸ்ப்பேர்த்துச் , மருத்துவ தலைப்புகள் , இதயம் தோல்வி , எடுப்போசை இதயம் ,

Bristol Myers Squibb Presents New Clinical and Real-World Data on Mavacamten and Obstructive Hypertrophic Cardiomyopathy at Upcoming American College of Cardiology's 70th Annual Scientific Session

New analysis of EXPLORER-HCM trial assessing impact of mavacamten on patient’s health status to be presented as late-breaking oral presentation Interim results of EXPLORER long-term extension study of mavacamten safety and efficacy data in patients with obstructive hypertrophic cardiomyopathy also to be presented Bristol Myers Squibb today announced that data from multiple studies across the company’s clinical …
New analysis of EXPLORER-HCM trial assessing impact of mavacamten on patient’s health status to be presented as late-breaking oral presentation
Interim results of EXPLORER long-term extension study of mavacamten safety and efficacy data in patients with obstructive hypertrophic cardiomyopathy (oHCM) ....

United States , Jay Edelberg , Johna Spertus , Bristol Myers Squibb , Susan Francis , Snehas Jain , Florian Rader , American College Of Cardiology , Clinical Researchi Session , Exchange Commission , Cardiomyopathy Development At Bristol Myers Squibb , Clinical Research , Health Status Benefits Of Mavacamten , Myers Squibb , American College , Annual Scientific Session , Kansas City Cardiomyopathy , Featured Clinical Researchi Session , Hot Topics Channel , Heart Failure , Cardiomyopathy Development , Bristol Myers , Status Benefits , Symptomatic Obstructive Cardiomyopathy , Results From , Clinical Trial ,